ClinicalTrials.Veeva

Menu

A Phase 3 Clinical Study of KHK4827

Kyowa Kirin logo

Kyowa Kirin

Status and phase

Completed
Phase 3

Conditions

Psoriasis

Treatments

Drug: KHK4827

Study type

Interventional

Funder types

Industry

Identifiers

NCT01782924
4827-003

Details and patient eligibility

About

This study is designed to evaluate safety and efficacy of long-term exposure of KHK4827 in subjects with moderate to severe plaque psoriasis who have completed the preceding Study 4827-002.

Enrollment

145 patients

Sex

All

Ages

20 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Subject has voluntarily signed the written informed consent form to participate in this study
  • Subject has completed the week 12 evaluation of Study 4827-002

Exclusion criteria

  • Subject has had a serious infection, defined as requiring systemic treatment with antibiotics or antivirals (excluding oral administration)
  • Subject has been judged to be ineligible for participation in the study by the investigators/subinvestigators

Trial design

145 participants in 2 patient groups

KHK4827 140mg SC
Experimental group
Treatment:
Drug: KHK4827
KHK4827 210mg SC
Experimental group
Treatment:
Drug: KHK4827

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems